Lupin, one of the leading pharmaceutical companies in India, announced today that the company has received final approval from the United States Food and Drug Administration (USFDA) for dermentia and anti-pregnancy tablets.

The company said, "Received dinal approval from USFDA for Donepezil Hydrochloride tablets, 23 mg and Blisovi 24 Fe tablets."

Donepezil Hydrochloride tablets are the are the AB rated generic version of Eisai's Aricept tablets, 23mg and are indicated for the treatment of dementia of the Alzheimer's type.

Similarly, Blisovi 24 Fe tablets are the are the AB rated generic version of Warner Chilcott's Loestrin 24 Fe Tablets and are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.

Lupin's US subsidiary, Lupin Pharmaceuticals would commence promoting both the products shortly in the US.

According to IMS MAT June 2015, Aricept and Loestrin 24 Fe had US sales of USD 52.3 million and USD 56.8 million respectively.

Shares of the company declined Rs 16.70, or 0.88%, to trade at Rs 1,883 at the BSE (Tuesday).